Capecitabine-induced-coronary-vasospasm leading to polymorphic ventricular tachycardia and cardiac arrest
Cardio-Oncology - 2024
Tóm tắt
Capecitabine, a pro-drug of 5-fluorouracil, is commonly used in the treatment of breast and colorectal cancer. Its side effects, including nausea, vomiting, diarrhea, fatigue, loss of appetite, and bone marrow suppression, are well recognized. However, coronary vasospasm represents a less commonly recognized but significant complication of fluoropyrimidine-based therapies such as capecitabine. Proposed mechanisms for this adverse effect complication include direct endothelium-independent vasoconstriction, activation of protein kinase C, and activation of the cyclooxygenase pathway. In this report, we present a case of capecitabine-induced coronary vasospasm leading to progressive, focal ST-elevations, myocardial ischemia, and subsequently polymorphic ventricular tachycardia. These events were captured on telemetry, in a male in his early 40s, diagnosed with stage IIIB sigmoid colon cancer. Notably, the patient had no pre-existing coronary artery disease or other cardiovascular risk factors. Upon diagnosis, the patient was initiated on a calcium channel blocker, verapamil, to mitigate further coronary vasospasm events. After thorough discussions that prioritized the patient’s input and values, an implantable cardioverter-defibrillator was placed subcutaneously. Following discharge, the patient restarted capecitabine therapy along with verapamil prophylaxis and did not experience any subsequent shocks from his ICD as assessed during his outpatient follow-up visits. This case emphasizes the need to involve patients in decision-making processes, especially when managing unexpected and serious complications, to ensure treatments align with their quality of life and personal preferences.
Từ khóa
Tài liệu tham khảo
Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140.
Fradley MG, Barrett CD, Clark JR, Francis SA. Ventricular fibrillation cardiac arrest due to 5-fluorouracil cardiotoxicity. Tex Heart Inst J. 2013;40(4):472–6.
Zafar A, Drobni ZD, Mosarla R, Alvi RM, Lei M, Lou UY, et al. The incidence, risk factors, and outcomes with 5-Fluorouracil–Associated Coronary Vasospasm. JACC CardioOncology. 2021;3(1):101–9.
Muco E, Patail H, Shaik A, McMahon S. Capecitabine-Associated Coronary Vasospasm and Cardiac arrest. Cureus. 2022;14(8):e28184.
Henry D, Rudzik F, Butts A, Mathew A. Capecitabine-Induced Coronary Vasospasm. Case Rep Oncol. 2016;9(3):629–32.
Aleem MS, Ghosh P, Sattur S. CORONARY VASOSPASM FROM COMBINATION CAPECITABINE AND OXALIPLATIN THERAPY. Chest. 2022;162(4):A248.
Golias C, Dimitriadis G, Dimitriadis D, Graidis C, Dimitrelos I, Tsiakou A, et al. Acute presentation of vasospastic angina induced by oral capecitabine: a case report. J Med Case Rep. 2014;8(1):18.
Mejia Morales M, Maroo P. Abstract 18001: coronary artery vasospasm secondary to Capecitabine: a Case Report. Circulation. 2023;148(Suppl1):A18001–1.
Depetris I, Marino D, Bonzano A, Cagnazzo C, Filippi R, Aglietta M, et al. Fluoropyrimidine-induced cardiotoxicity. Crit Rev Oncol Hematol. 2018;124:1–10.
Becker K, Erckenbrecht JF, Häussinger D, Frieling T. Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs. 1999;57(4):475–84.
Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993;53(13):3028–33.
Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al. Vascular toxicities of Cancer therapies: The Old and the New–An Evolving Avenue. Circulation. 2016;133(13):1272–89.
Fluoropyrimidine Cardiotoxicity. - American College of Cardiology [Internet]. [cited 2024 Jan 14]. Available from: https://www.acc.org/latest-in-cardiology/articles/2019/04/05/07/34/fluoropyrimidine-cardiotoxicity.
Arellano M, Malet-Martino M, Martino R, Gires P. The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer. 1998;77(1):79–86.
Cwikiel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M. The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc. 1996;10(3):805–18. discussion 819.
Tsibiribi P, Bui-Xuan C, Bui-Xuan B, Lombard-Bohas C, Duperret S, Belkhiria M, et al. Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol. 2006;25(6):305–9.
Polk A, Vistisen K, Vaage-Nilsen M, Nielsen DL. A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity. BMC Pharmacol Toxicol. 2014;15(1):47.
Yuan C, Parekh H, Allegra C, George TJ, Starr JS. 5-FU induced cardiotoxicity: case series and review of the literature. Cardio-Oncol. 2019;5(1):13.
Ambrosy AP, Kunz PL, Fisher GA, Witteles RM. Capecitabine-induced chest pain relieved by diltiazem. Am J Cardiol. 2012;110(11):1623–6.
Eskilsson J, Albertsson M. Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol Stockh Swed. 1990;29(8):1001–3.
de Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992;10(11):1795–801.
Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8(2):191–202.
Padegimas A, Carver JR. How to diagnose and manage patients with Fluoropyrimidine-Induced chest Pain. JACC CardioOncology. 2020;2(4):650–4.
Clasen SC, Ky B, O’Quinn R, Giantonio B, Teitelbaum U, Carver JR. Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm. J Gastrointest Oncol. 2017;8(6):970–9.
Tsavaris N, Kosmas C, Vadiaka M, Skopelitis E, Kopteridis P, Pamouki S, et al. 5-fluorouracil cardiotoxicity is a rare, dose and schedule-dependent adverse event: a prospective study. J BUON off J Balk Union Oncol. 2005;10(2):205–11.
Padegimas Allison C, Joseph R. How to diagnose and manage patients with Fluoropyrimidine-Induced chest Pain. JACC CardioOncology. 2020;2(4):650–4.
Desai A, Mohammed T, Patel KN, Almnajam M, Kim AS. 5-Fluorouracil Rechallenge after Cardiotoxicity. Am J Case Rep. 2020;21:e924446–1.
Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullén S, et al. Hypothermia versus Normothermia after Out-of-hospital cardiac arrest. N Engl J Med. 2021;384(24):2283–94.
Viskin S, Chorin E, Viskin D, Hochstadt A, Schwartz AL, Rosso R. Polymorphic ventricular tachycardia: terminology, mechanism, diagnosis, and Emergency Therapy. Circulation. 2021;144(10):823–39.
Lanza GA, Pedrotti P, Pasceri V, Lucente M, Crea F, Maseri A. Autonomic changes associated with spontaneous coronary spasm in patients with variant angina. J Am Coll Cardiol. 1996;28(5):1249–56.
Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ, Ganz P, et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med. 1991;325(22):1551–6.
Pitts WR, Lange RA, Cigarroa JE, Hillis LD. Cocaine-induced myocardial ischemia and infarction: pathophysiology, recognition, and management. Prog Cardiovasc Dis. 1997;40(1):65–76.
Hung MJ, Hu P, Hung MY. Coronary artery spasm: review and update. Int J Med Sci. 2014;11(11):1161–71.
Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation. 2011;124(16):1774–82.
Raizner AE, Chahine RA, Ishimori T, Verani MS, Zacca N, Jamal N, et al. Provocation of coronary artery spasm by the cold pressor test. Hemodynamic, arteriographic and quantitative angiographic observations. Circulation. 1980;62(5):925–32.
Specchia G, de Servi S, Falcone C, Bramucci E, Angoli L, Mussini A, et al. Coronary arterial spasm as a cause of exercise-induced ST-segment elevation in patients with variant angina. Circulation. 1979;59(5):948–54.
Tamura A, Nagao K, Inada T, Tanaka M. Exercise-induced vasospastic angina with prominent ST elevation: a case report. Eur Heart J Case Rep. 2018;2(4):yty141.